share_log

Goldman Sachs Maintains Sell on FibroGen, Lowers Price Target to $2

Benzinga ·  Jun 27, 2023 08:10

Goldman Sachs analyst Paul Choi maintains FibroGen (NASDAQ:FGEN) with a Sell and lowers the price target from $16 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment